JP7556848B2 - ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物 - Google Patents
ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物 Download PDFInfo
- Publication number
- JP7556848B2 JP7556848B2 JP2021514344A JP2021514344A JP7556848B2 JP 7556848 B2 JP7556848 B2 JP 7556848B2 JP 2021514344 A JP2021514344 A JP 2021514344A JP 2021514344 A JP2021514344 A JP 2021514344A JP 7556848 B2 JP7556848 B2 JP 7556848B2
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- human
- mrna
- seq
- mrna encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108020004999 messenger RNA Proteins 0.000 title claims description 1032
- 206010028980 Neoplasm Diseases 0.000 title claims description 174
- 239000000203 mixture Substances 0.000 title claims description 98
- 201000011510 cancer Diseases 0.000 title claims description 82
- 238000000034 method Methods 0.000 title claims description 50
- 239000003814 drug Substances 0.000 title description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 293
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 278
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 276
- 229920001184 polypeptide Polymers 0.000 claims description 276
- 102000056003 human IL15 Human genes 0.000 claims description 275
- 150000002632 lipids Chemical class 0.000 claims description 256
- 108010065805 Interleukin-12 Proteins 0.000 claims description 249
- 102000013462 Interleukin-12 Human genes 0.000 claims description 249
- 239000002773 nucleotide Substances 0.000 claims description 249
- 125000003729 nucleotide group Chemical group 0.000 claims description 249
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 claims description 152
- 241000282414 Homo sapiens Species 0.000 claims description 149
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 136
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims description 133
- 102000051450 human TNFSF4 Human genes 0.000 claims description 132
- 230000003834 intracellular effect Effects 0.000 claims description 121
- 239000002105 nanoparticle Substances 0.000 claims description 121
- 150000001875 compounds Chemical class 0.000 claims description 109
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 94
- 239000012528 membrane Substances 0.000 claims description 89
- 108090000172 Interleukin-15 Proteins 0.000 claims description 73
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 73
- 102000003812 Interleukin-15 Human genes 0.000 claims description 72
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 65
- 210000000822 natural killer cell Anatomy 0.000 claims description 58
- 229940068065 phytosterols Drugs 0.000 claims description 52
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 49
- 235000012000 cholesterol Nutrition 0.000 claims description 47
- 230000027455 binding Effects 0.000 claims description 46
- 230000002708 enhancing effect Effects 0.000 claims description 45
- 102000004473 OX40 Ligand Human genes 0.000 claims description 44
- 108010042215 OX40 Ligand Proteins 0.000 claims description 44
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 41
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 41
- 229950005143 sitosterol Drugs 0.000 claims description 41
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 claims description 35
- 150000003904 phospholipids Chemical class 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 34
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 32
- 150000002148 esters Chemical class 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 32
- 101710194995 Interleukin-12 subunit alpha Proteins 0.000 claims description 31
- 229940076810 beta sitosterol Drugs 0.000 claims description 31
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 29
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 29
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 29
- 229930182558 Sterol Natural products 0.000 claims description 28
- 150000003432 sterols Chemical class 0.000 claims description 28
- 235000003702 sterols Nutrition 0.000 claims description 28
- 108091008606 PDGF receptors Proteins 0.000 claims description 23
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 23
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 22
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 20
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 20
- 229940032091 stigmasterol Drugs 0.000 claims description 20
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 20
- 235000016831 stigmasterol Nutrition 0.000 claims description 20
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 18
- 108091051828 miR-122 stem-loop Proteins 0.000 claims description 18
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 claims description 16
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 16
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 16
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 claims description 16
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 12
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 claims description 12
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 12
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 12
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 12
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 claims description 12
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 claims description 12
- 230000000259 anti-tumor effect Effects 0.000 claims description 12
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 claims description 12
- 235000004420 brassicasterol Nutrition 0.000 claims description 12
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 12
- 235000000431 campesterol Nutrition 0.000 claims description 12
- 108091066112 miR-122-1 stem-loop Proteins 0.000 claims description 12
- 108091057488 miR-122-2 stem-loop Proteins 0.000 claims description 12
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 claims description 12
- 230000003213 activating effect Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims description 10
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims description 10
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims description 10
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims description 10
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims description 10
- 102000018697 Membrane Proteins Human genes 0.000 claims description 10
- 108010052285 Membrane Proteins Proteins 0.000 claims description 10
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims description 10
- 235000015500 sitosterol Nutrition 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- DGNMJYUPWDTKJB-ZDSKVHJSSA-N bis[(z)-non-2-enyl] 9-[4-(dimethylamino)butanoyloxy]heptadecanedioate Chemical compound CCCCCC\C=C/COC(=O)CCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC(=O)OC\C=C/CCCCCC DGNMJYUPWDTKJB-ZDSKVHJSSA-N 0.000 claims description 8
- 230000004069 differentiation Effects 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 6
- 108091007780 MiR-122 Proteins 0.000 claims description 6
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 6
- 108091023045 Untranslated Region Proteins 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- 108091070501 miRNA Proteins 0.000 claims description 6
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims description 6
- 230000002601 intratumoral effect Effects 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 230000001988 toxicity Effects 0.000 claims description 5
- 231100000419 toxicity Toxicity 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 238000007385 chemical modification Methods 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 claims description 3
- MUSPKJVFRAYWAR-XVFCMESISA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)S[C@H]1N1C(=O)NC(=O)C=C1 MUSPKJVFRAYWAR-XVFCMESISA-N 0.000 claims description 3
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 claims description 3
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 claims description 3
- JCNGYIGHEUKAHK-DWJKKKFUSA-N 2-Thio-1-methyl-1-deazapseudouridine Chemical compound CC1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O JCNGYIGHEUKAHK-DWJKKKFUSA-N 0.000 claims description 3
- BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 claims description 3
- CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 claims description 3
- JUMHLCXWYQVTLL-KVTDHHQDSA-N 2-thio-5-aza-uridine Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)N=C1 JUMHLCXWYQVTLL-KVTDHHQDSA-N 0.000 claims description 3
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 claims description 3
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 claims description 3
- FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 claims description 3
- HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 claims description 3
- VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 claims description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 3
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 claims description 3
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 claims description 3
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 3
- YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 claims description 3
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 3
- 108700011259 MicroRNAs Proteins 0.000 claims description 3
- 229930185560 Pseudouridine Natural products 0.000 claims description 3
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 3
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 3
- 229960003852 atezolizumab Drugs 0.000 claims description 3
- 229950002916 avelumab Drugs 0.000 claims description 3
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 3
- 229950009791 durvalumab Drugs 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- 239000002679 microRNA Substances 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 3
- 229950007217 tremelimumab Drugs 0.000 claims description 3
- 102000050320 human TNFRSF4 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 252
- 108700026244 Open Reading Frames Proteins 0.000 description 108
- 241000699670 Mus sp. Species 0.000 description 93
- 101000764258 Mus musculus Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 86
- 210000004379 membrane Anatomy 0.000 description 76
- 238000000684 flow cytometry Methods 0.000 description 67
- 229940117681 interleukin-12 Drugs 0.000 description 67
- 102000004127 Cytokines Human genes 0.000 description 53
- 108090000695 Cytokines Proteins 0.000 description 53
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 45
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 37
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 37
- 239000003937 drug carrier Substances 0.000 description 36
- 210000001165 lymph node Anatomy 0.000 description 32
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 28
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 28
- 239000003550 marker Substances 0.000 description 28
- 210000000952 spleen Anatomy 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 27
- 210000001185 bone marrow Anatomy 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 230000004913 activation Effects 0.000 description 24
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 23
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 23
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 22
- 210000000581 natural killer T-cell Anatomy 0.000 description 21
- 230000000139 costimulatory effect Effects 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 14
- 108010076504 Protein Sorting Signals Proteins 0.000 description 14
- 241000282567 Macaca fascicularis Species 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 125000005647 linker group Chemical group 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 230000006051 NK cell activation Effects 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000035800 maturation Effects 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 230000006044 T cell activation Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000003393 splenic effect Effects 0.000 description 8
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 7
- 102100022341 Integrin alpha-E Human genes 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 5
- -1 amino lipid Chemical class 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 3
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000038504 B7-1 Antigen Human genes 0.000 description 2
- 108010035053 B7-1 Antigen Proteins 0.000 description 2
- 101150014003 Batf3 gene Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 101001039696 Homo sapiens Lysophospholipid acyltransferase 7 Proteins 0.000 description 2
- 101000600779 Homo sapiens Neuromedin-B receptor Proteins 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 2
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 2
- 102000014154 Interleukin-12 Subunit p35 Human genes 0.000 description 2
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 description 2
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 101710089528 T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 101710180188 T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 102000054189 human CD80 Human genes 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000005931 immune cell recruitment Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101000858054 Mus musculus C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 101001055166 Mus musculus Interleukin-15 Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 102200117775 rs3213096 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731335P | 2018-09-14 | 2018-09-14 | |
| US62/731,335 | 2018-09-14 | ||
| US201862770024P | 2018-11-20 | 2018-11-20 | |
| US62/770,024 | 2018-11-20 | ||
| US201962881322P | 2019-07-31 | 2019-07-31 | |
| US62/881,322 | 2019-07-31 | ||
| PCT/US2019/051072 WO2020056304A1 (en) | 2018-09-14 | 2019-09-13 | Methods and compositions for treating cancer using mrna therapeutics |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501336A JP2022501336A (ja) | 2022-01-06 |
| JP2022501336A5 JP2022501336A5 (https=) | 2022-09-20 |
| JPWO2020056304A5 JPWO2020056304A5 (https=) | 2022-09-20 |
| JP7556848B2 true JP7556848B2 (ja) | 2024-09-26 |
Family
ID=68104746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514344A Active JP7556848B2 (ja) | 2018-09-14 | 2019-09-13 | ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230081530A1 (https=) |
| EP (1) | EP3849589A1 (https=) |
| JP (1) | JP7556848B2 (https=) |
| CN (1) | CN113015540A (https=) |
| AU (1) | AU2019338535A1 (https=) |
| CA (1) | CA3112781A1 (https=) |
| WO (1) | WO2020056304A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US20220280639A1 (en) * | 2019-07-31 | 2022-09-08 | Modernatx, Inc. | Compositions and methods for delivery of rna interference agents to immune cells |
| JP2023526059A (ja) * | 2020-05-14 | 2023-06-20 | モダーナティエックス・インコーポレイテッド | ｍＲＮＡ治療薬及びエフェクター分子を含むＬＮＰ組成物 |
| US12188060B2 (en) | 2020-05-15 | 2025-01-07 | Crispr Therapeutics Ag | Messenger RNA encoding Cas9 for use in genome-editing systems |
| WO2022010764A1 (en) * | 2020-07-06 | 2022-01-13 | Vivtex Corporation | Mucopenetrating formulations |
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| WO2022120560A1 (zh) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
| US20240200106A1 (en) * | 2021-04-17 | 2024-06-20 | Intellia Thrapeutics, Inc. | Lipid nanoparticles compositions |
| CN116406426A (zh) * | 2021-04-29 | 2023-07-07 | 苏州沙砾生物科技有限公司 | 一种修饰的肿瘤浸润淋巴细胞及其用途 |
| US20220364078A1 (en) | 2021-05-14 | 2022-11-17 | Crispr Therapeutics Ag | Mrna large scale synthesis and purification |
| US12251471B2 (en) * | 2021-07-26 | 2025-03-18 | Oregon State University | Inhalable therapeutics |
| CN114457054A (zh) * | 2022-02-24 | 2022-05-10 | 中国科学技术大学 | 一种cGAS mRNA的制备及作为免疫激活剂的应用 |
| US20250312430A1 (en) * | 2022-03-30 | 2025-10-09 | The Johns Hopkins University | Compositions of lipid nanoparticles for plasmid dna delivery to the liver and methods for preparing the same |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| CN119486749A (zh) * | 2022-06-22 | 2025-02-18 | 武汉厚先生物医药有限公司 | Il-12和ox40l组合物在肿瘤免疫治疗中的应用 |
| WO2024015955A2 (en) * | 2022-07-15 | 2024-01-18 | President And Fellows Of Harvard College | Mucispirillum compositions and cancer treatment methods thereof |
| US20250387486A1 (en) * | 2022-08-09 | 2025-12-25 | Stemirna Therapeutics Co., Ltd. | Lipid composition |
| CN115869332A (zh) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 |
| EP4649087A2 (en) | 2023-01-11 | 2025-11-19 | Engage Biologics Inc. | Non-viral expression systems and methods of use thereof |
| EP4470559A1 (en) * | 2023-06-02 | 2024-12-04 | Imgen-T-Srl | Combination containing an mrna vaccine and an immune modulating mrna for improved immunogenicity and efficacy |
| WO2025098508A1 (zh) * | 2023-11-10 | 2025-05-15 | 贝达药业股份有限公司 | 标记性多肽、治疗剂及其应用 |
| CN119662655A (zh) * | 2023-12-04 | 2025-03-21 | 武汉厚先生物医药有限公司 | Rna分子及其组合物在肿瘤免疫治疗中的应用 |
| WO2026078565A1 (en) | 2024-10-10 | 2026-04-16 | Crispr Therapeutics Ag | Messenger rna encoding cas9 for use in genome-editing systems |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016048903A1 (en) | 2014-09-22 | 2016-03-31 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| WO2017201350A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
| WO2018068008A1 (en) | 2016-10-07 | 2018-04-12 | Board Regents, The University Of Texas System | T cells expressing membrane-anchored il-12 for the treatment of cancer |
| WO2019152557A1 (en) | 2018-01-30 | 2019-08-08 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
| JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2390331B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| NZ582330A (en) * | 2007-06-27 | 2012-05-25 | Marinepolymer Tech Inc | COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| MX342785B (es) | 2009-06-10 | 2016-10-12 | Alnylam Pharmaceuticals Inc | Formulacion mejorada de lipido. |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US20140200261A1 (en) | 2013-01-17 | 2014-07-17 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| RU2749113C2 (ru) * | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| RS63135B1 (sr) * | 2015-12-23 | 2022-05-31 | Modernatx Inc | Postupci upotrebe polinukleotida koji kodiraju ox40 ligand |
| EP3458474B1 (en) * | 2016-05-18 | 2022-07-06 | ModernaTX, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
-
2019
- 2019-09-13 US US17/275,832 patent/US20230081530A1/en not_active Abandoned
- 2019-09-13 WO PCT/US2019/051072 patent/WO2020056304A1/en not_active Ceased
- 2019-09-13 CN CN201980074987.2A patent/CN113015540A/zh active Pending
- 2019-09-13 JP JP2021514344A patent/JP7556848B2/ja active Active
- 2019-09-13 EP EP19780053.5A patent/EP3849589A1/en active Pending
- 2019-09-13 CA CA3112781A patent/CA3112781A1/en active Pending
- 2019-09-13 AU AU2019338535A patent/AU2019338535A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016048903A1 (en) | 2014-09-22 | 2016-03-31 | Intrexon Corporation | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| WO2017201350A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
| WO2018068008A1 (en) | 2016-10-07 | 2018-04-12 | Board Regents, The University Of Texas System | T cells expressing membrane-anchored il-12 for the treatment of cancer |
| JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
| WO2019152557A1 (en) | 2018-01-30 | 2019-08-08 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
| JP2021512090A (ja) | 2018-01-30 | 2021-05-13 | モデルナティーエックス， インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
Non-Patent Citations (3)
| Title |
|---|
| Gene Therapy，2015年，Vol.22，p.696-706 |
| Int. J. Oncol.，2016年，Vol.48，p.2381-2386 |
| J Immunol，2004年，173(6)，pp.3716-3724 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3112781A1 (en) | 2020-03-19 |
| CN113015540A (zh) | 2021-06-22 |
| US20230081530A1 (en) | 2023-03-16 |
| JP2022501336A (ja) | 2022-01-06 |
| AU2019338535A1 (en) | 2021-04-15 |
| WO2020056304A1 (en) | 2020-03-19 |
| EP3849589A1 (en) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7556848B2 (ja) | ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物 | |
| ES2992653T3 (en) | Methods of preparing lipid nanoparticles | |
| ES2932516T3 (es) | Combinaciones de ARNm que codifican polipéptidos inmunomoduladores y usos de los mismos | |
| JP7285220B2 (ja) | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 | |
| US20210128721A1 (en) | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides | |
| ES3036912T3 (en) | Neoantigens and methods of their use | |
| JP2023510308A (ja) | 寛容原性樹状細胞を作る方法 | |
| JP2022177007A (ja) | がんの治療のためのｍＲＮＡ併用療法 | |
| US20190314291A1 (en) | Compositions and methods for delivery of agents to immune cells | |
| JP2022552371A (ja) | 免疫調節ポリペプチドをコードするｍＲＮＡ及びその使用 | |
| JP2019526556A (ja) | 癌治療用ｒｎａ | |
| JP2022531461A (ja) | 免疫細胞活性を破壊するポリヌクレオチド及びその使用方法 | |
| TW202245808A (zh) | 用於治療癌症之治療性ｒｎａ | |
| JP2023512072A (ja) | 代謝リプログラミングポリペプチドをコードするｍＲＮＡ及びその使用 | |
| CN116829578B (zh) | 编码白细胞介素-12(il-12)的多核苷酸以及其相关组合物和方法 | |
| JP7750525B2 (ja) | 新規なｔｌｒ９アゴニスト | |
| HK40050969A (en) | Methods and compositions for treating cancer using mrna therapeutics | |
| HK40099663A (zh) | 用於治疗癌症的治疗性rna | |
| RU2773273C2 (ru) | Неоантигены и способы их использования | |
| WO2023196988A1 (en) | Methods of use of mrnas encoding il-12 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220909 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220909 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230623 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230627 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230926 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240305 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240502 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240604 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240827 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240912 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7556848 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |